Secretory protein

Abstract

The disclosure of the present application relates to a secretory deleted split hand/split foot 1 (sDSS1) protein, the amino acid sequence thereof, the nucleic acid sequence thereof, and the applications of the same. The sDSS1 protein is a secretory protein from higher primate, and can be detected in human serum and cerebral spinal fluid (CSF). The sDSS1 protein can form conjugate with oxidized protein under nonenzymatic condition or with amyloid-beta (Aβ) polypeptide to reduce formation of Aβ oligomer. The addition of sDSS1 protein to culture medium can shield the cytotoxicity induced by oxidized protein, Aβ oligomer, amylin oligomer and glycosylated protein, so as to protect the cells against these toxoproteins. The sDSS1 protein can prolong survival time of senescence-accelerated mice significantly. The protein can be used to prevent and treat the diseases induced by oxidized protein, glycated protein, Aβ protein accumulation, amylin protein accumulation or excessive formation or accumulation of other pathogenic proteins with similar features, and has important potential in biological medicine.

1 - 18 . (canceled) 
     
     
         19 . A composition comprising:
 (i) a polypeptide having an amino acid sequence at least 80% identical to any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15 and SEQ ID NO. 16; or   (ii) a nucleic acid encoding said polypeptide of (i),   which composition has been formulated for administration to a subject.   
     
     
         20 . The composition of  claim 19 , wherein the polypeptide comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1. 
     
     
         21 . The composition of  claim 19 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1. 
     
     
         22 . The composition of  claim 19 , wherein the nucleic acid comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 17. 
     
     
         23 . The composition of  claim 19 , wherein the polypeptide comprises a fusion protein. 
     
     
         24 . The composition of  claim 23 , wherein the fusion protein comprises the polypeptide fused to itself or a fragment thereof. 
     
     
         25 . The composition of  claim 23 , wherein the fusion protein comprises the polypeptide fused to a carrier protein. 
     
     
         26 . The composition of  claim 23 , wherein the fusion protein comprises the polypeptide fused to an antibody. 
     
     
         27 . The composition of  claim 19 , wherein the polypeptide is complexed with a pharmaceutically acceptable carrier. 
     
     
         28 . The composition of  claim 27 , wherein the pharmaceutically acceptable carrier comprises one or more of microspheres, vesicles, liposomes, microemulsions, nanoparticles, magnetic particles, or gels. 
     
     
         29 . The composition of  claim 19 , wherein the polypeptide further comprises a pharmaceutically acceptable excipient. 
     
     
         30 . The composition of  claim 19 , wherein the polypeptide is complexed with a pathogenic polypeptide selected from the group consisting of advanced oxidation protein products (AOPP), amyloid-β, amylin, and glycosylated protein. 
     
     
         31 . The composition of  claim 30 , wherein the pathogenic polypeptide is advanced oxidation protein products (AOPP). 
     
     
         32 . The composition of  claim 30 , wherein the pathogenic polypeptide is amyloid-β. 
     
     
         33 . The composition of  claim 30 , wherein the pathogenic polypeptide is amylin. 
     
     
         34 . The composition of  claim 30 , wherein the pathogenic polypeptide is glycosylated protein. 
     
     
         35 . The composition of  claim 19 , wherein the polypeptide is complexed with a pathogenic polypeptide, wherein the pathogenic polypeptide is glycated protein. 
     
     
         36 . A method for treating or preventing dementia in a subject, the method comprising administering a composition of  claim 19  in an effective amount to the subject in need thereof. 
     
     
         37 . The method of  claim 36 , wherein the dementia is Alzheimer's Disease (AD). 
     
     
         38 . A method for treating or preventing type II diabetes in a subject, the method comprising administering a composition of  claim 19  in an effective amount to the subject in need thereof.